Oral semaglutide is available to prescribe again and is now effectively the only GLP-1 receptor agonist available. So, this is an opportune time for ABCD members to contribute to the ABCD oral semaglutide audit. As with all our audits, all contributors will be acknowledged in publications emanating from the audit and the biggest contributors will become co-authors. For those not already registered for the audit visit https://abcd.care/application-join-abcd-oral-semaglutide-audit-and-gain… to register.
Date of Announcement:
Image: Dr. Bob Ryder
Consultant Diabetologist
